Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762

Journal of Immunology

Volumn 156, Issue 10, 1996, Pages 3841-3849

  Frey, Alan B ^a,b  

^a Kaplan Cancer Center   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; HOST RESISTANCE; IMMUNE RESPONSE; MACROPHAGE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; T LYMPHOCYTE SUBPOPULATION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; GRAFT REJECTION; IMMUNIZATION, PASSIVE; LYMPHOCYTE DEPLETION; MALE; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; RECEPTORS, ANTIGEN; TUMOR CELLS, CULTURED;

EID: 0029980578     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Greenberg. P. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
2. Hamaoka, T., and H. Fujiwara 1987. Phenotypically and functionally distinct T-cell subsets in anti-tumor responses Immunol Today 8:267.
3. North, R., A. Digiacom, and E. Dye 1987 Suppression of antitumor immunity in Tumor Immunology-Mechanisms, Diagnosis, and Therapy. W. D. Otter and E. Ruitenberg, eds. Elsevier, New York, p. 125
4. + cells in tumor regression Jpn. J. Cancer Res 80:649.
5. Yoshizawa, H., A Chang, and S Shu. 1992 Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/IL2-activated tumor-draining lymph node cells. Cancer Res 52:1129.
6. Houghton, A 1994. Cancer antigens. immune recognition of self and altered self. J. Exp. Med. 180:1.
7. Bannerji, R , C. Arroyo, C. Cordon-Cardo, and E. Gilboa. 1994 The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity J Immunol 152:2324
8. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene J. Immunol. 149:3627.
9. Dranoff, G , E. Jaffe, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D Pardoll, and R. Mulligan. 1993 Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Nad Acad Sci USA 90: 3339.
10. + T cell-mediated tumor rejection and development of antitumor immunity. J. Immunol. 153:4604
11. Forni, G. M. Giovarelli, A Santoni, A. Modesti, and M. Forni. 1987. IL-2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J. Immunol 138:4033
12. + MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo J. Immunol 154 4613.
13. Hock, H , M Dorsch, U Kunzendorf, K. Uberla, Z. Qin, T. Diamantstein, and T. Blankentein 1993. Vaccination with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 53 714
14. Hock, H., M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein. 1993. Mechanisms of rejection induced by tumor cell-targeted gene transfer of IL2, IL4, IL7, TNF or IFN. Proc. Natl Acad. Sci. USA 90:2774.
15. + lymphocyte-driven and cosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153:5659.
16. Stoppacciaro, A., C. Melani, M. Parenza, A Mastracchio, C. Bassi, C. Baroni, G. Parmiani, and M. Columbo. 1993 Regression of an established tumor genetically modified to release GM-CSF requires granulocyte-T cell cooperation and T cell-produced IFN-γ. J. Exp. Med. 178:151.
17. Mantovani, A., B. Bottazzi, F. Colotta, S. Sozzani, and L Ruco. 1992. The origin and function of tumor-associated macrophages. Immunol Today 13:265.
18. Frey, A., and L Appleman. 1993. Rat adenocarcinoma 13762 expresses tumor rejection antigens but tumor-bearing animais exhibit tumor-specific immune suppression. Clin. Immunol Immunopathol. 69:223.
19. Brideau, F., P. Carter, and W. McMaster. 1980 Two subsets of rat T lymphocytes defined with monoclonal antibodies. Eur. J. Immunol 10:609
20. Chambers, W., N. Vujanvic, A. DeLeo, M. Olszowy, R. Herberman, and J Hiserodt. 1989. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J. Exp. Med. 169:1373.
21. Sekiya, S., S. Gotoh, T. Yamashita, T. Watanabe, S. Saitoh, and F. Sendo. 1989. Selective depletion of rat neutrophils by in vivo administration of a monoclonal antibody. J. Leukocyte Biol. 46:96.
22. Dallman, D, M. Thomas, and J. Green 1984. MRC OX-19: a monoclonal antibody that labels rat T lymphocytes and augments in vitro proliferative responses. Eur. J. Immunol 14:260.
23. Jefferies, W., J Green, and A. Williams 1985. Authentic T helper CD4 (W3/25) antigen on rat peritoneal macrophages. J. Exp. Med. 162:117.
24. Brink, M. v d., L Hunt, and J. Hiserodt. 1990. In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats. J. Exp. Med. 171:197.
25. Frey, A. 1996. T cell immunity to cancer. In Study of Immune Response to Tumors in the Rat. P. K Srivastava, ed. Academic Press, Miami, In press.
26. Debrick, J., P. Campbell, and U. Staerz 1991 Macrophages as accessory cells for class I MHC-restricted immune responses. J. Immunol. 147:2846.
27. + T cells in vivo. Proc Natl. Acad. Sci. USA 91:3077.
28. Webb, M., D. Mason, and A Williams. 1979. Inhibition of mixed lymphocyte response by a monoclonal antibody specific for a rat T lymphocyte subset. Nature 282:841.
29. + T cells m the presence of a nondepleting monoclonal antibody to CD4 induces a Th2-type response in vitro. J Exp. Med 182:5
30. +) T lymphocyte recruitment into subcutaneous tissues of rats by selective depletion of in vivo neutrophils with a monoclonal antibody. J Immunol. 147:2196.
31. + T cells are required for resistance to secondary tumor challenge. Immunology 61:317.
32. Golumbek, P., A. Lazenby, H. Levitsky, L. Jaffe, H. Karsuyama, H. Baker, and D. Pardoll. 1991 Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:719.
33. Karp, S., A. Farber, J. Salo, P. Hwu, G. Jaffe, A. Asher, E. Shiloni, N. Restifo, J. Mule, and S. Rosenberg 1993. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J. Immunol. 150:896.
34. Okuda, K , K. Tani, Y. Ishigatsubo, S. Yokota, and C. David. 1980. Antigen-pulsed neutrophils bearing Ia antigens can induce T lymphocytes proliferative response to the syngeneic or semisyngeneic antigen-primed T lymphocytes. Transplantation 30:364
35. Yamake, T., T. Ude, N. Shijubo, and K Kikuchi. 1988. Functional analysis of mononuclear cells infiltrating into tumors. J. Immunol. 140:4388.
36. Pardoll, D, 1995 Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399.
37. Julius, H., E. Simpson, and L. Herzenberg. 1973. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur. J. Immunol 3:645.